Human 27-hydroxycholesterol ELISA Kit,Abbkine,KTE62711

• Do not mix components from different kit lots or use reagents beyond the kit expiration date.• Allow all reagents to warm to room temperature for at least 30 minutes before opening.• Pre-rinse the pipet tip with reagent, use fresh pipet tips for each sample, standard and reagent to avoid contamination. • Unused wells must be kept desiccated at 4 °C in the sealed bag provided.• Mix Thoroughly is very important for the result. It is recommended using low frequency oscillator or slight hand shaking every 10 minutes.• It is recommended that all samples and standards be assayed in duplicate or triplicate.

Platform ID

BAB886452443

Abbkine

Headquarters

3052 Stroop Hill Road, Apt 203, Atlanta 30303, Georgia, United States of America

Contact

Tel: +1-404-854-0155
Fax:

Product Specifications
Scientific Background
Synonyms

Specifications

NameHuman 27-hydroxycholesterol ELISA Kit
Cat. No.KTE62711
ShippingThe unopened kit should be stored at 2 - 8°C. After opening, please store refer to protocols.
StorageThe unopened kit should be stored at 2 - 8°C. After opening, please store refer to protocols.
Regulatory StatusResearch Use Only

Scientific Background

27-Hydroxycholesterol (27-HC) is an endogenous oxysterol with multiple biological functions, including activity as a selective estrogen receptor modulator (SERM) (a mixed, tissue-specific agonist-antagonist of the estrogen receptor (ER)) and as an agonist of the liver X receptor (LXR). It is a metabolite of cholesterol that is produced by the enzyme CYP27A1. A link between high cholesterol and breast cancer has been identified, and it has been proposed that this is due to 27-HC production by CYP27A1. Because of its estrogenic action, 27-HC stimulates the growth of ER-positive breast cancer cells, and has been implicated in limiting the effectiveness of aromatase inhibitors in the treatment of breast cancer. As such, identified CYP27A1 inhibitors, including the marketed drugs anastrozole, fadrozole, bicalutamide, dexmedetomidine, ravuconazole, and posaconazole, have been proposed as potential adjuvant therapies in ER-positive breast cancer.

Synonyms

27HC

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.